SAN DIEGO, CALIFORNIA, UNITED STATES, January 4, 2022 /EINPresswire.com/ — Gravitas Therapeutics, Inc. (“Gravitas”), a clinical-stage biopharmaceutical company engaged in the development of GR-2397 (previously VL-2397, ASP2397), a novel first-in-class antifungal agent for the treatment of immunocompromised patients with serious fungal infections, today announced the appointment of Bill Enright, CEO of Vaccitech, plc (NASDAQ: VACC; “Vaccitech”), as an independent director to its Board of Directors. In December 2021 Gravitas announced the purchase of GR-2397.

“Bill brings an impressive track record of leading multiple infectious disease-focused biopharmaceutical companies, including raising significant monies in private and public financings,” said Tom Smart, Chairman and CEO of Gravitas. “We believe Bill’s background and leadership skills will aid Gravitas achieving its financing and product development objectives.”

“Gravitas is in an advantageous position to pursue the accelerated development and registration of GR-2397 via the Limited Population Pathway for Antibacterial and Antifungal Drugs. This follows considerable prior research and development investments resulting in the successful completion of single and multiple ascending dose Phase 1 studies,” said Mr. Enright. “I look forward to supporting Gravitas’ expedited, cost-efficient quest to realize GR-2397’s potential to address the significant unmet medical need for better therapeutics to treat severe fungal infections.”

In 2019, Mr. Enright was appointed CEO of Vaccitech, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. In that role, Mr. Enright has raised over $250 million, completed an initial public offering, and acquired Avidea Technologies to expand both Vaccitech’s product pipeline and scientific leadership. Prior to joining Vaccitech, Mr. Enright served as CEO of Altimmune Inc, a company developing novel immunotherapies and vaccines. He led Altimmune through a significant period of growth including a Series B financing, the acquisition of Immune Targeting Systems – a UK T-cell vaccine company – and taking the company public on NASDAQ through the acquisition of PharmAthene. Mr. Enright’s prior experience includes executive and management roles at GenVec (now Intrexon), Biotech Venture Management and Life Technologies Corporation (now ThermoFisher). Read More